Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

CORK, Ireland, Oct. 1, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

"Simeprevir's clinical profile has been characterized through a robust clinical development program including more than 3,700 patients," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen. "The study results that will be presented at the AASLD Annual Meeting support the potential utility of simeprevir in a number of different hepatitis C patient populations."

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3, 8:00 a.m. - 5:30 p.m. (EST)

  • Simeprevir (TMC435) with peg-interferon alpha-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient sub-populations in the PROMIS
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Acquire Exclusive Rights to Gastrin Based Therapies Program for ... ... TORONTO, March 13 Eli Lilly,and Company (NYSE: LLY ) ... two companies have entered into a licensing,and collaboration agreement granting Lilly ...
... KANSAS CITY, Mo., March 13 Synbiotics Corporation ... the Food & Drug,Administration (FDA) for the use ... in humans. This represents Synbiotics first foray into ... Synbiotics,initial intent to market this product itself to ...
Cached Medicine Technology:Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 2Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 3Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 4Synbiotics Corporation Announces Human Submission for FluDetect(R) 2
(Date:9/2/2015)... Boston, MA (PRWEB) , ... September 02, 2015 ... ... reports covering healthcare innovation and investment, announced the two leaders who will deliver ... Boston on November 3, at the Mandarin Oriental Hotel in Boston. , Larry ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and ... mixed documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps ... to reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... on the development and commercialization of proprietary pharmaceuticals ... partners , today announced that under the Special ... with the United States Food and Drug Administration ... protocol for crofelemer for the treatment of chronic ...
... Functional foods could be the rage today in advanced ... better ask some tough questions before they decide ... ,Currently the international functional foods market is a ... ,* Margarines that lower bad cholesterol (LDL). ...
... at the University of Southern California have applied a ... clear up an old puzzle of the global carbon ... an advanced online publication of The ISME Journal. ... for nanometer-scale, secondary ion mass spectrometry) located at Lawrence ...
... to get hookah smoking exempted from Englands smoking ban ... the health effects , doctors writing in this weeks ... ,A hookah is a glass based waterpipe used ... for smoking herbal fruits after meals, but it is ...
... disease gives a more accurate measure of how many UK ... adults are most likely to benefit from treatment . ... the general population without pre-existing cardiovascular disease or diabetes, there ... Britain at high risk of developing heart disease. This is ...
... and Children's Hospital, Adelaide in Australia has raised serious questions ... are exposed to every day. ,Titled The ... ageing facilities in two of the hospital's oldest buildings and ... ,It states: "WCH is experiencing immediate facilities, infrastructure and related ...
Cached Medicine News:Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
Inquire...
... K2 / gel tubes are for ... molecular diagnostics and for viral load ... blood remain stable at room temperature ... optimal results, it is recommended to ...
Glass Whole Blood Tube with K3EDTA...
... transglutaminase (tTg) is a ubiquitous enzyme ... Tissue transglutaminase is also the specific ... endomysial antibody immunofluorescence (EMA) tests (Bio-Rad ... IgA and,IgG serologic tests are highly ...
Medicine Products: